Immuneering Statistics
Total Valuation
Immuneering has a market cap or net worth of $337.72 million. The enterprise value is $158.68 million.
| Market Cap | 337.72M |
| Enterprise Value | 158.68M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 64.70 million shares outstanding. The number of shares has increased by 76.62% in one year.
| Current Share Class | 64.70M |
| Shares Outstanding | 64.70M |
| Shares Change (YoY) | +76.62% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 14.12% |
| Owned by Institutions (%) | 49.80% |
| Float | 49.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.77 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.47, with a Debt / Equity ratio of 0.02.
| Current Ratio | 19.47 |
| Quick Ratio | 18.47 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.15% and return on invested capital (ROIC) is -34.90%.
| Return on Equity (ROE) | -52.15% |
| Return on Assets (ROA) | -32.77% |
| Return on Invested Capital (ROIC) | -34.90% |
| Return on Capital Employed (ROCE) | -32.73% |
| Weighted Average Cost of Capital (WACC) | 6.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.00M |
| Employee Count | 57 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.83% in the last 52 weeks. The beta is 0.37, so Immuneering's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +38.83% |
| 50-Day Moving Average | 4.61 |
| 200-Day Moving Average | 5.36 |
| Relative Strength Index (RSI) | 64.65 |
| Average Volume (20 Days) | 663,072 |
Short Selling Information
The latest short interest is 15.40 million, so 23.81% of the outstanding shares have been sold short.
| Short Interest | 15.40M |
| Short Previous Month | 15.21M |
| Short % of Shares Out | 23.81% |
| Short % of Float | 31.30% |
| Short Ratio (days to cover) | 17.87 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -63.47M |
| Pretax Income | -57.28M |
| Net Income | -57.28M |
| EBITDA | -63.12M |
| EBIT | -63.47M |
| Earnings Per Share (EPS) | -$0.98 |
Balance Sheet
The company has $149.90 million in cash and $3.63 million in debt, with a net cash position of $179.04 million or $2.77 per share.
| Cash & Cash Equivalents | 149.90M |
| Total Debt | 3.63M |
| Net Cash | 179.04M |
| Net Cash Per Share | $2.77 |
| Equity (Book Value) | 190.74M |
| Book Value Per Share | 2.95 |
| Working Capital | 149.87M |
Cash Flow
In the last 12 months, operating cash flow was -$56.75 million and capital expenditures -$238,462, giving a free cash flow of -$56.99 million.
| Operating Cash Flow | -56.75M |
| Capital Expenditures | -238,462 |
| Depreciation & Amortization | 349,852 |
| Net Borrowing | n/a |
| Free Cash Flow | -56.99M |
| FCF Per Share | -$0.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immuneering does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -76.62% |
| Shareholder Yield | -76.62% |
| Earnings Yield | -16.96% |
| FCF Yield | -16.88% |
Analyst Forecast
The average price target for Immuneering is $18.25, which is 249.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.25 |
| Price Target Difference | 249.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |